10-Q: Delcath Systems Reports Q2 2026 Growth, Clinical Trial Progress

Delcath Systems, Inc. announced its second quarter 2026 financial results, showcasing a significant increase in product revenue driven by HEPZATO sales and positive developments in ongoing clinical trials.

Summary

• Delcath Systems reported total revenues of $29.1 million for the three months ended June 30, 2026, an increase from $24.2 million in the same period of 2025.
• For the six months ended June 30, 2026, total revenues were $54.1 million, up from $43.9 million in the prior year.
• Net income for the three months ended June 30, 2026, was $2.7 million, compared to $2.7 million in the prior year.
• Net income for the six months ended June 30, 2026, was $1.6 million, a decrease from $3.8 million in the prior year.
• The company had cash and cash equivalents of $47.5 million and short-term investments of $48.4 million as of June 30, 2026.
• Research and development expenses increased to $10.4 million for the three months ended June 30, 2026, from $6.9 million in the prior year, reflecting ongoing clinical trial activities.
• Selling, general, and administrative expenses rose to $13.4 million for the three months ended June 30, 2026, from $11.4 million in the prior year, due to commercial expansion.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting continued revenue growth and progress in clinical trials, balanced by ongoing R&D investments and market uncertainties.

Positives

• Total revenue increased by 20.6% to $29.1 million for the three months ended June 30, 2026, compared to $24.2 million in the prior year.
• Total revenue increased by 23.1% to $54.1 million for the six months ended June 30, 2026, compared to $43.9 million in the prior year.
• HEPZATO KIT revenue grew to $27.2 million for the three months ended June 30, 2026, from $22.5 million in the prior year.
• The company maintains a strong liquidity position with $47.5 million in cash and cash equivalents and $48.4 million in short-term investments as of June 30, 2026.
• Positive results from the investigator-initiated CHOPIN clinical trial showed improved progression-free survival and overall survival for the combination group.
• The company has sufficient raw material and component parts for HEPZATO KIT to meet anticipated demand.

Negatives

• Net income decreased to $1.6 million for the six months ended June 30, 2026, from $3.8 million in the same period of 2025.
• Research and development expenses increased significantly by 50.8% to $10.4 million for the three months ended June 30, 2026, impacting profitability.
• Selling, general, and administrative expenses also increased by 17.7% to $13.4 million for the three months ended June 30, 2026.
• The company has a substantial accumulated deficit of $527.3 million as of June 30, 2026.
• A reserve of $0.5 million was included for inventory expected to expire prior to usage during the six months ended June 30, 2026.

Risks

• The company is subject to risks common to biopharmaceutical companies, including uncertainties in product development, commercialization, and obtaining regulatory approvals.
• Geopolitical events, global health outbreaks, and supply chain disruptions could impact manufacturing, clinical trials, and costs.
• The company's revenue is generated from a concentrated group of customers, and a delay or dispute with a significant customer could adversely affect operating cash flow.
• The company may face challenges in obtaining and maintaining sufficient reimbursement for its products and procedures.
• Competition from other therapeutic options could lead to loss of revenue or market share.
• The company is exploring new indications for HEPZATO, which involves significant R&D investment and regulatory hurdles.

Future Outlook

The company believes its current cash, cash equivalents, and investments are sufficient to support operations for at least 12 months. Future liquidity needs will depend on clinical trial progress, regulatory approvals, commercialization efforts, and intellectual property management. R&D expenses are expected to increase due to ongoing Phase 2 clinical trials for mCRC and mBC.

Management Comments

• The Company believes that HEPZATO has the potential to treat other cancers in the liver, such as metastatic colorectal cancer, metastatic breast cancer, metastatic neuroendocrine tumors, and intrahepatic cholangiocarcinoma.
• We expect that this will support increased clinical adoption of and reimbursement for CHEMOSAT in Europe, and to support reimbursement in various jurisdictions, including the United States for HEPZATO.
• We believe that these and similar disease states are areas of unmet medical needs that represent significant market opportunities.
• We expect our research and development expenses to increase for the foreseeable future relating to the costs required to complete these Phase 2 clinical trials.

Industry Context

StockSavvy.ai notes that Delcath Systems operates in the competitive interventional oncology space, focusing on liver-directed therapies. The company's strategy involves expanding the indications for its HEPZATO KIT and CHEMOSAT, leveraging clinical trial data to drive adoption and reimbursement, particularly in the United States and Europe.

Comparison to Industry Standards

• The FOCUS Trial's Objective Response Rate (ORR) of 36.3% (including 7.7% Complete Response) for mUM was statistically significantly better than the pooled ORR estimate of 5.5% in the historical control group, indicating a strong performance relative to historical benchmarks for this indication.
• The CHOPIN trial demonstrated a one-year progression-free survival rate of 54.7% in the combination group versus 15.8% in the PHP group, a significant improvement that surpasses typical outcomes for monotherapy treatments in similar advanced melanoma patient populations.
• The company's R&D spending as a percentage of revenue for the six months ended June 30, 2026, was approximately 37.3% ($20.2M / $54.1M), which is high but not unusual for companies in the clinical-stage biopharmaceutical sector investing heavily in pipeline development.
• The company's gross profit margin of approximately 91.3% for the three months ended June 30, 2026 ($26.1M / $29.1M) is very strong, suggesting efficient cost management of goods sold relative to revenue, which is a positive indicator in the pharmaceutical industry.

Legal Proceedings

• The medac Matter involves a dispute over a milestone payment under a License, Supply and Marketing Agreement, which was settled with ongoing royalty payments or minimum annual payments from Delcath to medac.

Stakeholder Impact

• Shareholders: Continued revenue growth and clinical trial progress are positive indicators, but increased R&D expenses and a substantial accumulated deficit present ongoing concerns. The share repurchase program may benefit shareholders through potential increases in EPS.
• Customers (Hospitals/Treatment Centers): Continued availability of HEPZATO and CHEMOSAT, with ongoing clinical data supporting their efficacy and potential for reimbursement.
• Suppliers: Continued demand for melphalan and other components for HEPZATO KIT production.
• Creditors: The company's liquidity position appears sufficient for the near term, reducing immediate concerns for creditors.

Next Steps

• Continue generating clinical data for CHEMOSAT and HEPZATO to support increased clinical adoption and reimbursement.
• Enroll approximately 90 patients in the Phase 2 trial for liver-dominant mCRC, with expected hPFS readout by end of 2027 and OS in 2028.
• Enroll approximately 90 patients in the Phase 2 trial for liver-dominant HER2-negative mBC, with expected hPFS readout by end of 2028 and OS in 2029.
• Continue monitoring the implementation and effect of tariffs and geopolitical events.
• Manage supply chain risk through stockpiled inventory and multiple suppliers for critical components.

Key Dates

Recommendation

Delcath Systems shows promising revenue growth and positive clinical trial data, particularly for HEPZATO. However, the significant increase in R&D expenses, ongoing accumulated deficit, and reliance on a few key customers introduce considerable risk. The company's future success hinges on successful commercialization and reimbursement for new indications, which carries inherent uncertainty. Therefore, a 'hold' recommendation is appropriate, pending further clarity on clinical trial outcomes and market penetration.

Keywords

HEPZATO KIT, CHEMOSAT, Interventional Oncology, Uveal Melanoma, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Hepatic Delivery System, Clinical Trials